Clinical Trial Update: LBH589 in Refractory Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial of LBH589 in refractory myelodysplastic syndromes was terminated with posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• LBH589 (panobinostat)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Myelodysplastic Syndromes (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2012-12-19